IPO registrations (S-1, F-1) · Registrants
Lexaria Bioscience Corp.
- SEC CIK
- 1348362 · filings on EDGAR ↗
- Former names
- Lexaria Corp. (2008–2016); LEXARIA CORP. (2008–2016)
- Registration
- Form S-1, first filed 2011-07-21, last 2025-12-05; 9 initial registrations, 6 amendments
- Outcome
- Final prospectus filed 2021-01-14; declared effective 2011-08-04; withdrawal requested 2012-05-29
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- NV
- Business address
- 100 - 740 MCCURDY ROAD, Kelowna, A1 V1X 2P7
- EIN
- 20-2000871
- Ticker
- LEXX (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Lexaria Bioscience Corp. on the corporate pages
Offering terms
- Final price
- $5.25 per share (424B4 filed 2021-01-14)
- Shares sold
- 1,828,571
- Gross proceeds
- $9,599,997 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol LEXX
- Lead underwriters
- H.C. Wainwright
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: Lexaria Bioscience Corp. EXACT (CIK (EXACT))
- SEC filer: Lexaria Bioscience Corp. EXACT (CIK (EXACT))
- Person page: Brian W Quigley Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 42
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2011-07-21 | S-1 | S-1 (registration) | LEXARIA CORP. | 0001204459-11-001972 ↗ |
| 2011-08-04 | EFFECT | EFFECT (declared effective) | LEXARIA CORP. | 9999999995-11-002392 ↗ |
| 2012-03-15 | S-1 | S-1 (registration) | LEXARIA CORP. | 0001204459-12-000531 ↗ |
| 2012-05-29 | RW | RW (withdrawal request) | LEXARIA CORP. | 0001204459-12-001283 ↗ |
| 2012-05-31 | S-1/A | S-1/A (amendment) | LEXARIA CORP. | 0001204459-12-001296 ↗ |
| 2012-06-22 | S-1/A | S-1/A (amendment) | LEXARIA CORP. | 0001204459-12-001435 ↗ |
| 2012-07-02 | EFFECT | EFFECT (declared effective) | LEXARIA CORP. | 9999999995-12-002019 ↗ |
| 2018-03-07 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-18-000547 ↗ |
| 2020-06-03 | S-1 | S-1 (registration) | Lexaria Bioscience Corp. | 0001640334-20-001402 ↗ |
| 2020-06-11 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-20-001408 ↗ |
| 2020-11-20 | S-1 | S-1 (registration) | Lexaria Bioscience Corp. | 0001640334-20-002897 ↗ |
| 2021-01-06 | S-1/A | S-1/A (amendment) | Lexaria Bioscience Corp. | 0001640334-21-000033 ↗ |
| 2021-01-07 | S-1/A | S-1/A (amendment) | Lexaria Bioscience Corp. | 0001640334-21-000047 ↗ |
| 2021-01-11 | S-1MEF | S-1MEF (added securities) | Lexaria Bioscience Corp. | 0001640334-21-000059 ↗ |
| 2021-01-11 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-21-000105 ↗ |
| 2021-01-14 | 424B4 | 424B4 (final prospectus) | Lexaria Bioscience Corp. | 0001640334-21-000086 ↗ |
| 2021-03-03 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-21-000801 ↗ |
| 2021-12-23 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-21-004795 ↗ |
| 2021-12-23 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-21-004797 ↗ |
| 2022-02-04 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-22-000347 ↗ |
| 2022-12-22 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-22-003611 ↗ |
| 2022-12-29 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-22-003658 ↗ |
| 2023-04-03 | S-1 | S-1 (registration) | Lexaria Bioscience Corp. | 0001640334-23-000549 ↗ |
| 2023-04-28 | S-1/A | S-1/A (amendment) | Lexaria Bioscience Corp. | 0001640334-23-000723 ↗ |
| 2023-05-08 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-23-001333 ↗ |
| 2023-05-10 | 424B4 | 424B4 (final prospectus) | Lexaria Bioscience Corp. | 0001640334-23-000798 ↗ |
| 2023-11-30 | S-1 | S-1 (registration) | Lexaria Bioscience Corp. | 0001640334-23-002255 ↗ |
| 2023-12-08 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-23-003580 ↗ |
| 2024-01-26 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-24-000222 ↗ |
| 2024-03-12 | S-1 | S-1 (registration) | Lexaria Bioscience Corp. | 0001640334-24-000388 ↗ |
| 2024-03-20 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-24-000695 ↗ |
| 2024-06-03 | S-1 | S-1 (registration) | Lexaria Bioscience Corp. | 0001640334-24-000898 ↗ |
| 2024-06-11 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-24-001816 ↗ |
| 2024-12-05 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-24-003680 ↗ |
| 2024-12-17 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-24-003799 ↗ |
| 2025-01-30 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-25-000249 ↗ |
| 2025-10-14 | S-1 | S-1 (registration) | Lexaria Bioscience Corp. | 0001640334-25-001839 ↗ |
| 2025-12-05 | S-1/A | S-1/A (amendment) | Lexaria Bioscience Corp. | 0001640334-25-002256 ↗ |
| 2025-12-08 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-25-003563 ↗ |
| 2025-12-09 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-25-003607 ↗ |
| 2026-01-14 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-26-000171 ↗ |
| 2026-10-13 | EFFECT | EFFECT (declared effective) | Lexaria Bioscience Corp. | 9999999995-26-003231 ↗ |
Prospectus pages read 3
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-01-06 | S-1/A | registration statement | $7.50 | 1,066,666 | $7,998,928 | OTCQX LXRP | 1 | primary document; price sentence, shares headline, proceeds computed, cover names 1 | document ↗ | |
| 2021-01-07 | S-1/A | registration statement | - | - | 0 | primary document; no terms found | document ↗ | |||
| 2021-01-14 | 424B4 | final prospectus | $5.25 | 1,828,571 | $9,599,997 | Nasdaq LEXX | 1 | primary document; price line, shares headline, proceeds computed, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| MacMillan Leonard | Director,Officer | President & PEO; Vice President - Corp Develop; Vice President-Corp Develop; VP - Corp. Development | 4 | 2006–2010 | |
| Rees Diane | Director,Officer | Chief Financial Officer, PAO | 1 | 2006 | |
| BUNKA CHRISTOPHER | Director; Director,Officer; Director,Officer,TenPercentOwner | CEO; CEO/Chairman; Chairmain/CEO/President/CFO; Chairman/CEO; Chairman/CEO/CFO; Chairman/CEO/President; Chairman,CEO,President,CFO; Chairman/CEO/President/CFO; Chairman, President & CEO; Chairman/President/CEO; Chariman/CEO/President; Chariman/CEO/President/CFO; Chief Executive Officer; President; President and CEO; President, CEO and CFO; President, C.E.O. and Chairman; President, CEO and Chairman | 258 | 2006–2026 | |
| Bhullar Baljinder | Director; Director,Officer; Other | CFO; Director/CFO | 13 | 2009–2025 | |
| DEMARTINI DAVID | Director; Director,TenPercentOwner | 10 | 2009–2013 | ||
| IHRKE THOMAS JAMES | Officer | Sr. VP, Business Developement; Sr. VP, Business Development | 4 | 2010–2011 | |
| ELFORD DUSTIN ARTHUR | Director | 1 | 2011 | ||
| Baxter Nicholas W | Director | 22 | 2011–2025 | ||
| DOCHERTY JOHN MARTIN | Director,Officer; Director,TenPercentOwner; Officer | President; President & CSO | 26 | 2015–2025 | |
| McKechnie William Edward | Director | 26 | 2015–2025 | ||
| Spissinger Allan Horst | Officer | CFO; Chief Financial Officer | 6 | 2017–2020 | |
| Quigley Brian W. | Director | 3 | 2019–2020 | person page Fuzzy | |
| REESE ALBERT L JR | Director | 11 | 2021–2025 | ||
| Carle Vanessa | Officer | Secretary | 12 | 2021–2025 | |
| Downey Gregory | Officer | Chief Financial Officer | 8 | 2021–2022 | |
| TURKEL CATHERINE C. | Director | 8 | 2022–2024 | ||
| Cabatuan Nelson | Officer | Chief Financial Officer | 1 | 2024 | |
| CHRISTOPHER RICHARD | Director,Officer; Officer | Chief Executive Officer | 4 | 2024–2025 | |
| Shankman Michael Elliot | Officer | Chief Financial Officer | 2 | 2024–2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2026-09-21 | Lexaria Bioscience Corp. | Biotechnology | $113,492 | $113,492 | 3 | 1 |
| 2025-12-19 | Lexaria Bioscience Corp. | Biotechnology | $3,500,004 | $3,500,004 | 5 | 1 |
| 2025-10-01 | Lexaria Bioscience Corp. | Biotechnology | $4,000,000 | $4,000,000 | 5 | 1 |
| 2024-10-16 | Lexaria Bioscience Corp. | Pharmaceuticals | $5,000,000 | $5,000,000 | 1 | 1 |
| 2024-05-02 | Lexaria Bioscience Corp. | Pharmaceuticals | $364,629 | $364,629 | 1 | 1 |
| 2024-02-16 | Lexaria Bioscience Corp. | Pharmaceuticals | $3,600,003 | $3,600,003 | 2 | 1 |
| 2023-10-04 | Lexaria Bioscience Corp. | Pharmaceuticals | $1,569,780 | $1,569,780 | 1 | 1 |
| 2021-12-20 | Lexaria Bioscience Corp. | Biotechnology | $1,200,000 | $1,200,000 | 1 | 1 |
| 2021-07-27 | Lexaria Bioscience Corp. | Biotechnology | $85,000 | $85,000 | 1 | 1 |
| 2020-07-08 | Lexaria Bioscience Corp. | Biotechnology | $100,000 | $100,000 | 1 | 1 |
| 2020-05-13 | Lexaria Bioscience Corp. | Other | $2,039,228 | $2,039,228 | 21 | 1 |
| 2019-11-19 | Lexaria Bioscience Corp. | Biotechnology | $2,357,594 | $492,500 | 5 | 1 |
| 2019-11-13 | Lexaria Bioscience Corp. | Biotechnology | $180,000 | $180,000 | 1 | 1 |
| 2018-11-15 | Lexaria Bioscience Corp. | Pharmaceuticals | $310,000 | $310,000 | 3 | 1 |
| 2016-09-13 | Lexaria Bioscience Corp. | Pharmaceuticals | $108,500 | $108,500 | 6 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Lexaria Bioscience Corp. | Form D private offerings | CIK (EXACT) | |
| SEC filer | Lexaria Bioscience Corp. | SEC filers (EDGAR) | CIK (EXACT) | |
| Person page | Brian W Quigley | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, A1 first:
- ONCOGENEX TECHNOLOGIES INC A1
- Aspreva Pharmaceuticals CORP A1
- Zymeworks BC Inc. A1
- BetterLife Pharma Inc. A1
- ABATTIS BIOCEUTICALS CORP A1
- BriaCell Therapeutics Corp. A1
- Old API Wind-down Ltd. A1
- AbCellera Biologics Inc. A1
- BODY & MIND INC. A1
- XORTX Therapeutics Inc. A1
In other datasets, the same topic (Health) in A1:
- Form D issuer: 1219014 B.C. Ltd. (Form D private offerings)
Interests: Pharmaceutical Preparations · Health